{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T22:06:47Z","timestamp":1748470007021},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T00:00:00Z","timestamp":1583712000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T00:00:00Z","timestamp":1583712000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1245\/s10434-020-08312-0","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T18:03:03Z","timestamp":1583776983000},"page":"1420-1429","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["International Multicenter Experience of Isolated Limb Infusion for In-Transit Melanoma Metastases in Octogenarian and Nonagenarian Patients"],"prefix":"10.1245","volume":"27","author":[{"given":"J\u00fcri","family":"Teras","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidde M.","family":"Kroon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John T.","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Kenyon-Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia M.","family":"Beasley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean","family":"Mullen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norma E.","family":"Farrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J.","family":"Mosca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael C.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara R.","family":"Farley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aishwarya","family":"Potdar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hala","family":"Daou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Carr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey M.","family":"Farma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Speakman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Serpell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith A.","family":"Delman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. Mark","family":"Smithers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Barbour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas S.","family":"Tyler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendon J.","family":"Coventry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan S.","family":"Zager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,9]]},"reference":[{"key":"8312_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"8312_CR2","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.jid.2016.01.035","volume":"136","author":"DC Whiteman","year":"2016","unstructured":"Whiteman DC, Green AC, Olsen CM. The growing burden of invasive melanoma: projections of incidence rates and numbers of new cases in six susceptible populations through 2031. J Invest Dermatol. 2016;136:1161\u201371.","journal-title":"J Invest Dermatol"},{"key":"8312_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.3353","author":"KG Paulson","year":"2019","unstructured":"Paulson KG, Gupta D, Kim TS, et al. Age-specific incidence of melanoma in the United States. JAMA Dermatol. 2019. https:\/\/doi.org\/10.1001\/jamadermatol.2019.3353.","journal-title":"JAMA Dermatol"},{"key":"8312_CR4","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199\u2013206.","journal-title":"J Clin Oncol"},{"key":"8312_CR5","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1067\/j.cpsurg.2011.02.002","volume":"48","author":"A Sanki","year":"2011","unstructured":"Sanki A, Kroon HM, Kam PC, Thompson JF. Isolated limb perfusion and isolated limb infusion for malignant lesions of the extremities. Curr Probl Surg. 2011;48:371\u2013430.","journal-title":"Curr Probl Surg"},{"key":"8312_CR6","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"A Eggermont","year":"2018","unstructured":"Eggermont A, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378:1789\u2013801.","journal-title":"N Engl J Med"},{"key":"8312_CR7","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1245\/s10434-019-07288-w","volume":"26","author":"JT Miura","year":"2019","unstructured":"Miura JT, Kroon HM, Beasley GM, et al. Long-term oncologic outcomes after isolated limb infusion for locoregionally metastatic melanoma: an international multicenter analysis. Ann Surg Oncol. 2019;26:2486\u201394.","journal-title":"Ann Surg Oncol"},{"key":"8312_CR8","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1245\/s10434-017-6046-5","volume":"24","author":"HM Kroon","year":"2017","unstructured":"Kroon HM, Coventry BJ, Giles MH, et al. Safety and efficacy of isolated limb infusion chemotherapy for advanced locoregional melanoma in elderly patients: an Australian multicentre study. Ann Surg Oncol. 2017;24:3245\u201351.","journal-title":"Ann Surg Oncol"},{"key":"8312_CR9","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/jso.23540","volume":"109","author":"HM Kroon","year":"2014","unstructured":"Kroon HM, Huismans A, Waugh RC, et al. Isolated limb infusion: technical aspects. J Surg Oncol. 2014;109:352\u20136.","journal-title":"J Surg Oncol"},{"key":"8312_CR10","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1245\/s10434-008-9988-9","volume":"15","author":"GM Beasley","year":"2008","unstructured":"Beasley GM, Petersen RP, Yoo J, et al. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol. 2008;15:2195\u2013205.","journal-title":"Ann Surg Oncol"},{"key":"8312_CR11","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/0277-5379(82)90235-8","volume":"18","author":"J Wieberdink","year":"1982","unstructured":"Wieberdink J, Benckhuysen C, Braat RP, et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol. 1982;18:905\u201310.","journal-title":"Eur J Cancer Clin Oncol"},{"key":"8312_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer."},{"key":"8312_CR13","volume-title":"World Health Organization (WHO) handbook for reporting results of cancer treatment","author":"RD Hunter","year":"1979","unstructured":"Hunter RD. World Health Organization (WHO) handbook for reporting results of cancer treatment. Geneva: WHO; 1979."},{"key":"8312_CR14","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1245\/s10434-017-5803-9","volume":"24","author":"MF Madu","year":"2017","unstructured":"Madu MF, Deken MM, van der Hage JA, et al. Isolated limb perfusion for melanoma is safe and effective in elderly patients. Ann Surg Oncol. 2017;24:1997\u20132005.","journal-title":"Ann Surg Oncol"},{"key":"8312_CR15","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1097\/SLA.0b013e3181a77ce5","volume":"249","author":"HM Kroon","year":"2009","unstructured":"Kroon HM, Lin DY, Kam PC, Thompson JF. Safety and efficacy of isolated limb infusion with cytotoxic drugs in elderly patients with advanced locoregional melanoma. Ann Surg. 2009;249:1008\u201313.","journal-title":"Ann Surg"},{"key":"8312_CR16","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1007\/BF02574514","volume":"9","author":"EM Noorda","year":"2002","unstructured":"Noorda EM, Vrouenraets BC, Nieweg OE, van Geel AN, Eggermont AM, Kroon BB. Safety and efficacy of isolated limb perfusion in elderly melanoma patients. Ann Surg Oncol. 2002;9:968\u201374.","journal-title":"Ann Surg Oncol"},{"key":"8312_CR17","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.ejso.2019.02.026","volume":"45","author":"HM Kroon","year":"2019","unstructured":"Kroon HM, Coventry BJ, Henderson MA, et al. Evaluation of the efficacy and toxicity of upper extremity isolated limb infusion chemotherapy for melanoma: an Australian multi-center study. Eur J Surg Oncol. 2019;45:832\u20137.","journal-title":"Eur J Surg Oncol"},{"key":"8312_CR18","unstructured":"World Health Organization. Countries [Internet]. Geneva: World Health Organization; 2019 [cited 2019 October 27]. www.who.int\/countries\/en\/."},{"key":"8312_CR19","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1172\/JCI64096","volume":"123","author":"E Montecino-Rodriguez","year":"2013","unstructured":"Montecino-Rodriguez E, Berent-Maoz B, Dorshkind K. Causes, consequences, and reversal of immune system aging. J Clin Invest. 2013,123:958\u201365.","journal-title":"J Clin Invest"},{"key":"8312_CR20","doi-asserted-by":"publisher","first-page":"628","DOI":"10.14336\/AD.2017.0103","volume":"8","author":"JR Aunan","year":"2017","unstructured":"Aunan JR, Cho WC, Soreide K. The biology of aging and cancer: a brief overview of shared and divergent molecular hallmarks. Aging Dis. 2017,8:628\u201342.","journal-title":"Aging Dis"},{"key":"8312_CR21","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","volume":"375","author":"AMM Eggermont","year":"2016","unstructured":"Eggermont AMM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in stage III melanoma with Ipilimumab adjuvant therapy. N Engl J Med. 2016;375:1845\u201355.","journal-title":"N Engl J Med"},{"key":"8312_CR22","first-page":"367","volume":"17","author":"National Comprehensive Cancer Network (NCCN)","year":"2019","unstructured":"National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: cutaneous melanoma, version 2.2019. JNCCN. 2019;17:367\u2013402.","journal-title":"JNCCN"},{"key":"8312_CR23","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00262-016-1952-0","volume":"66","author":"B Weide","year":"2017","unstructured":"Weide B, Neri D, Elia G. Intralesional treatment of metastatic melanoma: a review of therapeutic options. Cancer Immunol Immunother. 2017;66:647\u201356.","journal-title":"Cancer Immunol Immunother"},{"key":"8312_CR24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2217\/mmt-2016-0031","volume":"4","author":"BD Wernick","year":"2017","unstructured":"Wernick BD, Goel N, Zih FSW, Farma JM. A surgical perspective report on melanoma management. Melanoma Manag. 2017;4:105\u201312.","journal-title":"Melanoma Manag"},{"key":"8312_CR25","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/jso.21968","volume":"104","author":"KU Boyd","year":"2011","unstructured":"Boyd KU, Wehrli BM, Temple CL. Intra-lesional interleukin-2 for the treatment of in-transit melanoma. J Surg Oncol. 2011;104:711\u20137.","journal-title":"J Surg Oncol"},{"key":"8312_CR26","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Antbacka","year":"2015","unstructured":"Antbacka RH; Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rat in patients with advanced melanoma. J Clin Oncol. 2015;33:2780\u20138.","journal-title":"J Clin Oncol"},{"key":"8312_CR27","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1634\/theoncologist.2009-0325","volume":"15","author":"D Moreno-Ramirez","year":"2010","unstructured":"Moreno-Ramirez D, Cruz-Merino, L, Ferrandiz L, Villegas-Portero R, Nieto-Garcia A. Isolated limb perfusion for malignant melanoma: systemic review on effectiveness and safety. Oncologist. 2010;15:416\u201327.","journal-title":"Oncologist"},{"key":"8312_CR28","doi-asserted-by":"publisher","first-page":"106573","DOI":"10.1155\/2011\/106573","volume":"2011","author":"HM Kroon","year":"2011","unstructured":"Kroon HM. Treatment of locally advanced melanoma by isolated limb infusion with cytotoxic drugs. J Skin Cancer. 2011;2011:106573.","journal-title":"J Skin Cancer"},{"key":"8312_CR29","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s10585-018-9890-1","volume":"35","author":"ES Weitman","year":"2018","unstructured":"Weitman ES, Zager JS. Regional therapies for locoregionally advanced and unresectable melanoma. Clin Exp Metastasis. 2018;35:495\u2013502.","journal-title":"Clin Exp Metastasis"},{"key":"8312_CR30","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1080\/14712598.2016.1233961","volume":"16","author":"C Luu","year":"2016","unstructured":"Luu C, Khushalani NI, Zager JS. Intralesional and systemic immunotherapy for metastatic melanoma. Expert Opin Biol Ther. 2016;16:1491\u20139.","journal-title":"Expert Opin Biol Ther"},{"key":"8312_CR31","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377:1824\u201335.","journal-title":"N Engl J Med"},{"key":"8312_CR32","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.jamcollsurg.2008.12.019","volume":"208","author":"GM Beasley","year":"2009","unstructured":"Beasley GM, Caudle A, Petersen RP, et al. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg. 2009;208:706\u201315.","journal-title":"J Am Coll Surg"},{"key":"8312_CR33","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1245\/s10434-009-0326-7","volume":"16","author":"HM Kroon","year":"2009","unstructured":"Kroon HM, Lin DY, Kam PC, Thompson JF. Isolated limb infusion as palliative treatment for advanced limb disease in patients with AJCC stage IV melanoma. Ann Surg Oncol. 2009;16:1193\u2013201.","journal-title":"Ann Surg Oncol"},{"key":"8312_CR34","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1245\/s10434-012-2373-8","volume":"19","author":"GM Beasley","year":"2012","unstructured":"Beasley GM, Coleman AP, Raymond A, et al. A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity. Ann Surg Oncol. 2012;19:3896\u2013905.","journal-title":"Ann Surg Oncol"},{"key":"8312_CR35","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1158\/2326-6066.CIR-17-0356","volume":"6","author":"CE Ariyan","year":"2018","unstructured":"Ariyan CE, Brady MS, Siegelbaum RH, et al. Robust antitumor responses result from local chemotherapy and CTLA-4 blockade. Cancer Immunol Res. 2018;6:189\u2013200.","journal-title":"Cancer Immunol Res"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-08312-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-020-08312-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-08312-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T00:06:23Z","timestamp":1615248383000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-020-08312-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,9]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["8312"],"URL":"https:\/\/doi.org\/10.1245\/s10434-020-08312-0","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,9]]},"assertion":[{"value":"30 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.S.Z. Patent for high-flow ILI. J.F.T. GlaxoSmithKline and Provectus Inc.: honoraria and travel support for Advisory Board participation. B.M.S. Australia and MSD Australia: honoraria for Advisory Board participation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}